Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00994-24 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Mark A Marzinke und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections, Pyridones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), Bill and Melinda Gates Foundation (GF).
Abstract (Originalsprache)
HPTN 084 demonstrated the superiority of long-acting injectable cabotegravir (CAB-LA) compared with daily oral tenofovir disoproxil fumarate–emtricitabine (F/TDF) for HIV prevention in women. CAB-LA (600 mg) or placebo injections were administered 4 weeks after an initial dose (loading dose) and every 2 months (Q2M) thereafter; this is the approved regimen. Participants experienced both loading dose and Q2M delays during the trial. CAB concentrations were evaluated before a delay, at the visit associated with the delay, and the visit after a delayed injection was administered. During the blinded phase of the trial, 194 participants randomized to CAB-LA experienced at least one injection delay. Plasma CAB concentrations were maintained above the 4× protein adjusted 90% inhibitory concentration (4× PA-IC 90 ; protocol-specific threshold) for all loading dose and 98% of Q2M delays when injections were administered up to 6 weeks late. The feasibility of shifting to an every 3-month (Q3M) regimen in females was interrogated via simulation studies using a population pharmacokinetic model. Q3M injections in both CAB-naïve (with a loading dose) and previously CAB-exposed females were predicted to yield higher steady-state exposures than in males on the approved Q2M regimen. Although there is observed forgiveness following an isolated delayed CAB-LA injection and simulations suggest acceptable CAB-LA exposures in women with a 600 mg CAB-LA Q3M regimen, empirical efficacy of this regimen has not been established, and transitioning to this dosing schema is not recommended. Future pharmacokinetic bridging studies are aimed at evaluating higher dose CAB-LA formulations administered less frequently. CLINICAL TRIALS This study is registered with ClinicalTrials.gov as NCT03164564 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- GSK, Collegeville, Pennsylvania, USA.
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- FHI 360, Durham, North Carolina, USA.
- HIV and other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa.
ORCID-Profile: Mark A Marzinke, Kelong Han
Förderung
- NIAID NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- Bill and Melinda Gates Foundation (GF)
- ViiV Healthcare (ViiV Healthcare Limited)
Zitieren
APA
Marzinke, M. A., Han, K., Hanscom, B., Guo, X., Piwowar-Manning, E., Hendrix, C. W., Rose, S., Spooner, E., Mathew, C., Innes, S., Sekabira, R., Mutambanengwe, M., Rooney, J. F., Rinehart, A. R., Adeyeye, A., Cohen, M. S., Hosseinipour, M., Ford, S. L., & Delany-Moretlwe, S. (2024). Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00994-24
Vancouver
Marzinke MA, Han K, Hanscom B, Guo X, Piwowar-Manning E, Hendrix CW, et al. Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00994-24
BibTeX
@article{Marzinke2024,
author = {Marzinke, Mark A and Han, Kelong and Hanscom, Brett and Guo, Xu and Piwowar-Manning, Estelle and Hendrix, Craig W and Rose, Scott and Spooner, Elizabeth and Mathew, Carrie and Innes, Steven and Sekabira, Rogers and Mutambanengwe, Mercy and Rooney, James F and Rinehart, Alex R and Adeyeye, Adeola and Cohen, Myron S and Hosseinipour, Mina and Ford, Susan L and Delany-Moretlwe, Sinead},
title = {Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00994-24}
}
EUVIMED